Change of initial oral antidiabetic therapy in type 2 diabetic patients

Pharmacy World and Science

Volumn 31, Issue 6, 2009, Pages 622-626

  Plat, Arian ^a   Penning Van Beest, Fernie ^a   Kessabi, Sophia ^b   Groot, Martijn ^c   Herings, Ron ^a,d  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Novartis Pharma BV   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Diabetes; Netherlands; Oral antidiabetic agents; Pharmacoepidemiology; Treatment pattern

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADMINISTRATION, ORAL; ADULT; AGED; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; NETHERLANDS; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 76749137099     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-009-9321-0     Document Type: Article

References (9)

1. World Health Organisation [ www.who.int ]. Geneva: Diabetes Facts Sheets (2008); [cited 2009 February 26]. Available from: http://www.who.int/ mediacentre/factsheets/fs312/en/index.html/.
2. G Ukpds 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 854 865 10.1016/S0140- 6736(98)07037-8 (Pubitemid 28416719)
3. RM Herings A Bakker BH Stricker G Nap 1992 Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts J Epidemiol Community Health 46 136 140 10.1136/jech.46.2.136 1:STN:280: DyaK383mtVWgtQ%3D%3D 1349911
4. VS Catalan J Lelorier 2000 Predictors of long-term persistence on statins in a subsidized clinical population Value Health 3 417 426 10.1046/j.1524-4733. 2000.36006.x 1:STN:280:DC%2BD28%2FnvFCmuw%3D%3D 16464201 (Pubitemid 32066649)
5. JS Burgers JV Bailey NS Klazinga AK Van Der Bij R Grol G Feder 2002 Inside guidelines: comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries Diabetes Care 25 1933 1939 10.2337/diacare.25.11.1933 12401735 (Pubitemid 41071047)
6. JA Cramer A Roy A Burrell CJ Fairchild MJ Fuldeore DA Ollendorf, et al. 2008 Medication compliance and persistence: terminology and definitions Value Health 11 44 47 18237359
7. SJ Boccuzzi J Wogen J Fox JC Sung AB Shah J Kim 2001 Utilization of oral hypoglycemic agents in a drug-insured U.S. population Diabetes Care 24 1411 1415 10.2337/diacare.24.8.1411 1:STN:280:DC%2BD3MvktVOltg%3D%3D 11473078
8. GEHM Rutten WJC De Grauw G Nijpels AN Goudswaard PJM Uitewaal FEE Van der Does, et al. 2006 NHG-standaard diabetes mellitus type 2 (tweede herziening) [NHG Practice Guideline Diabetes Mellitus Type 2 (second revision)] Huisarts Wet 49 137 152
9. AJ Krentz CJ Bailey 2005 Oral antidiabetic agents: current role in type 2 diabetes mellitus Drugs 65 385 411 10.2165/00003495-200565030-00005 1:CAS:528:DC%2BD2MXit1Grsbg%3D 15669880 (Pubitemid 40227460)